Accolade, Inc.

ACCD

Explore Our Financial Data > Companies > Small Cap > Accolade, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ACCD
CIK	0001481646
SIC	7389
Sector	Services
Industry Category	Business Services
Industry Group	Services – Misc. Business Services

Contact

Address	660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING, PA, 19462
Website	accolade.com
Phone	610-834-2989
CEO	Rajeev Singh
Employees	2,350

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$446.72 million
Pre-Tax Income	$-178.53 million
Net Income	$-180.30 million
Net Income to Common	$-180.30 million
EPS	$-2.25

View All

Balance Sheet

Cash	$185.92 million
Assets	$647.45 million
Liabilities	$334.45 million
Common Equity	$313.00 million
Liabilities & Equity	$647.45 million

View All

Cash Flow Statement

Net Income	$-180.30 million
Cash From Operating Activities	$-6.76 million
Cash From Investing Activities	$-43.56 million
Cash From Financing Activities	$6.22 million
Change in Cash	$-44.10 million

View All

Calculations

NOPAT	$-129.08 million
EBITDA	$-138.90 million
Price to Earnings	N/A
Price to Book	$1.83
ROE	-48.23%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Accolade Stockholders Approve Merger Between Accolade and Transcarent

SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to c

Article Link

Is Accolade Inc. (NASDAQ:ACCD) the Best Performing Stock So Far In 2025?

We recently published a list of the 11 Best Performing Stocks So Far In 2025. In this article, we are going to take a look at where Accolade Inc. (NASDAQ:ACCD) stands against the other best performing stocks so far in 2025. On March 21, Jason Pride, Chief of Investment Strategy at Glenmede, and Stephen DeNichilo, […]

Article Link

Do Options Traders Know Something About Accolade (ACCD) Stock We Don't?

Investors need to pay close attention to Accolade (ACCD) stock based on the movements in the options market lately.

Article Link

Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

Accolade, Inc. (Nasdaq: ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

Article Link

Piper Sandler downgrades Accolade ahead of shareholder vote

Investing.com -- Piper Sandler downgraded Accolade Inc (NASDAQ:ACCD) to Neutral from Overweight and cut its price target to $7.03 per share, aligning with the proposed acquisition price in the company's pending sale to Transcarent.

Article Link